T98G Cell Line human

T98G has been used to study the effects of the lysosomal destabilizing drug Siramesine on glioblastoma. It has also been used to study the efficiency of empty spiracles homeobox 2 (EMX2) in suppressing glioblastoma.

Studies on the mechanism for cessation of proliferation in quiescent cells and cells synchronised in G1 phase.

Human Caucasian glioblastoma

Derived from glioblastoma multiform tumour from a 61-year-old Caucasian male. Indefinite lifespan and anchorage independent but can enter viable G1 arrested state when deprived of serum.

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 13
D16S539: 13
D5S818: 10,12
D7S820: 9,10
THO1: 7,9.3
TPOX: 8
vWA: 17,20

EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 1% Sodium Pyruvate (NaP) + 10% Foetal Bovine Serum (FBS).

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm² using 0.25% trypsin/EDTA; 5% CO₂; 37°C. Cells may become anchorage-independent if deprived of serum.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.